Clinical Trial Update: Long-term Safety in Atrial Fibrillation Patients [Phase 2]

View source ↗

Summary

A Phase 2 long-term safety trial in patients with persistent or permanent nonvalvular atrial fibrillation has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: AstraZeneca | Conditions: Persistent or Permanent Nonvalvular Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2012-03-06